High and Predictable Growth
Full Year 2023 Guidance Reaffirmed
NOVA LIMA, Brazil–(BUSINESS WIRE)–Afya Limited (Nasdaq: AFYA) (“Afya” or the “Company”), the leading medical education group and digital health services provider in Brazil, reported today financial and operating results for the three-month period ended March 31, 2023 (first quarter 2023). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS).
First Quarter 2023 Highlights
- 1Q23 Adjusted Net Revenue increased 25.0% YoY to R$709.4 million. Adjusted Net Revenue excluding acquisitions grew 13.5%, reaching R$644.3 million.
- 1Q23 Adjusted EBITDA increased 21.9% YoY reaching R$330.2 million, with an Adjusted EBITDA Margin of 46.5%. Adjusted EBITDA excluding acquisitions grew 12.3%, reaching R$304.2 million, with an Adjusted EBITDA Margin of 47.2%.
- Cash conversion of 111.9%, with a solid cash position of R$ 722.7 million.
- ~295 thousand monthly active physicians and medical students using Afya’s Digital Services.
| Table 1: Financial Highlights | ||||||
| For the three months period ended March 31, | ||||||
| (in thousand of R$) |
2023 |
2023 Ex Acquisitions* |
2022 |
% Chg |
% Chg Ex Acquisitions |
|
| (a) Net Revenue |
709,961 |
644,849 |
566,324 |
25.4% |
13.9% |
|
| (b) Adjusted Net Revenue (1) |
709,383 |
644,271 |
567,716 |
25.0% |
13.5% |
|
| (c) Adjusted EBITDA (2) |
330,211 |
304,231 |
270,801 |
21.9% |
12.3% |
|
| (d) = (c)/(b) Adjusted EBITDA Margin |
46.5% |
47.2% |
47.7% |
-120 bps | -50 bps | |
| *For the three months period ended March 31, 2023, “2023 Ex Acquisitions” excludes: Alem da Medicina (January & February 2023; Closing of Alem da Medicina was in March, 2022), Glic, Cardiopapers and UNIT Alagoas and FITS Jaboatão dos Guararapes (all from January to March, 2023). | ||||||
| (1) Includes mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction and excludes any recovery of these discounts that were invoiced based on the Supreme Court decision. | ||||||
| (2) See more information on “Non-GAAP Financial Measures” (Item 07). | ||||||
Message from Management
For us in Afya, these results indicate another great start for the year ahead. We are proud to present, once again, strong results, reaffirming the success and resilience of Afya, along with high and predictable growth, and a solid cash generation.
This quarter was marked by significant increases in net revenue within our three segments and we are delighted to see that the most significant growth came from our Continue Education segment with a robust intake process, six new campuses, and course maturation.
Our second most significant growth came from our core business, as we saw higher tickets in Medicine courses, maturation of medical seats, the beginning of 4 Mais Médicos campuses, consolidation of UNIT Alagoas and FITS Jaboatão dos Guararapes acquisition, and the consolidation of 92 new medical seats, 28 in the UniSL Ji-Paraná campus, located in Rondônia, and 64 in Faculdade Santo Agostinho, in the city of Itabuna, situated in the state of Bahia.
And, once again, Afya reported great results on the Digital Health Services revenue, which ended the quarter with an increase of 20% when compared to last year. This result reinforces the opportunity ahead in Digital Services, and it is explained by the ramp-up in B2B engagements, with new contracts with the pharmaceutical industry companies, and the continuous ramp-up in B2P contracts, as we will discuss further on.
High and predictable growth, strong guidance for the year, and segments ramp-up: this proves how we are evolving and empowering our vision to transform health together with those who have medicine as a vocation. We are proud of our business and also excited for what comes next during this year.
1. Key Events in the Quarter:
- Afya announced on January 2nd, 2023, the closing of its acquisition of 100% of the total share capital of Sociedade Educacional e Cultural Sergipe DelRey Ltda. (“DelRey”), that encompasses the operations of Centro Universitário Tiradentes Alagoas (“UNIT Alagoas”) and Faculdade Tiradentes Jaboatão dos Guararapes (“FITS Jaboatão dos Guararapes”), on the terms previously disclosed.
- Afya announced on January 31st, 2023, that it is one of 484 companies across 45 countries and regions to join the 2023 Bloomberg Gender-Equality Index (GEI), a modified market capitalization-weighted index that aims to track the performance of public companies committed to transparency in gender-data reporting. This reference index measures gender equality across five pillars: leadership & talent pipeline, equal pay & gender pay parity, inclusive culture, anti-sexual harassment policies, and external brand. For the second time in a row, Afya was included on the index for scoring above a global threshold established by Bloomberg to reflect disclosure and the achievement or adoption of best-in-class statistics and policies, being 1 of 16 Brazilian companies included in the index this year.
- Fourth share repurchase program, on March 2023 – the Board of Directors approved a new share repurchase program. Under this share repurchase program, Afya may repurchase up to 2,000,000 of its outstanding Class A common shares which represents approximately 5.8% of its free float in accordance with the conditions established by the Board of Directors on March 24, 2023. Accordingly, in connection with repurchases under the new program, Afya also announced that entered into a written trading plan with BofA Securities, Inc., as the independent broker-dealer, which is intended to comply with the requirements of Rule 10b5-1 and Rule 10b-18 each under the Securities and Exchange Act of 1934, as amended.
2. 2023 Guidance
The Company is reaffirming its previously issued guidance for 2023 which considers the successfully concluded acceptances of new students, ensuring 100% occupancy in all of its medical schools.
Considering the above factors, the guidance for 2023 is defined in the following table:
| Guidance for 2023 | ||
| Adjusted Net Revenue* | R$ 2,750 mn ≤ ∆ ≤ R$ 2,850 mn | |
| Adjusted EBITDA | R$ 1,100 mn ≤ ∆ ≤ R$ 1,200 mn | |
| Includes UNIT Alagoas and FITS Jaboatão dos Guararapes’ acquisitions; Includes the increase of 64 medical seats of Faculdade Santo Agostinho, in the city of Itabuna; Excludes any acquisition that may be concluded after the issuance of the guidance. |
||
3. 1Q23 Overview
Operational Review
Afya is the only Company offering educational and technological solutions to support physicians across every stage of their medical career, from undergraduate students in their medical school years through medical residency preparatory courses, medical specialization programs, and continuing medical education. The Company also offers solutions to empower physicians in their daily routine, including supporting clinic decisions through mobile app subscription, delivering practice management tools through a Software as a Service (SaaS) model, and assisting physicians in their relationship with their patients.
The Company reports results for three distinct business units – the first, Undergrad – medical schools, other healthcare programs, and ex-health degrees. Revenue is generated from the monthly tuition fees the Company charges students enrolled in the undergraduate programs – the second, Continuing Education – specialization programs and graduate courses for physicians. Revenue is also generated from the monthly tuition fees the Company charges students enrolled in the specialization and graduate courses. The third is Digital Services – digital services offered by the Company at every stage of the medical career. This business unit is divided into Business to Physician (which encompasses Content & Technology for Medical Education, Clinical Decision Software, Practice Management Tools & Electronic Medical Records, Physician-Patient Relationship, Telemedicine, and Digital Prescription) and Business to Business (which provides access and demand for the healthcare players). Revenue is generated from printed books and e-books and is recognized at the point in time when control is transferred to the customer, and subscription fees, which are recognized as the services, are transferred over time.
Key Revenue Drivers – Undergraduate Courses
| Table 2: Key Revenue Drivers | Three months period ended March 31, | ||
|
2023 |
2022 |
% Chg | |
| Undergrad Programs | |||
| MEDICAL SCHOOL | |||
| Approved Seats |
3,163 |
2,759 |
14.6% |
| Operating Seats |
3,113 |
2,481 |
25.5% |
| Total Students (end of period) |
20,822 |
17,523 |
18.8% |
| Average Total Students |
20,822 |
17,523 |
18.8% |
| Average Total Students (ex-Acquisitions)* |
18,819 |
17,523 |
7.4% |
| Tuition Fees (Total – R$ ‘000) |
630,960 |
501,523 |
25.8% |
| Tuition Fees (ex- Acquisitions* – R$ ‘000) |
573,747 |
501,523 |
14.4% |
| Medical School Gross Avg. Ticket (ex- Acquisitions* – R$/month) |
10,163 |
9,540 |
6.5% |
| Medical School Net Avg. Ticket (ex- Acquisitions* – R$/month) |
8,517 |
7,861 |
8.3% |
| UNDERGRADUATE HEALTH SCIENCE | |||
| Total Students (end of period) |
21,660 |
20,902 |
3.6% |
| Average Total Students |
21,660 |
20,902 |
3.6% |
| Average Total Students (ex-Acquisitions)* |
19,788 |
20,902 |
-5.3% |
| Tuition Fees (Total – R$ ‘000) |
97,968 |
78,310 |
25.1% |
| Tuition Fees (ex- Acquisitions* – R$ ‘000) |
90,296 |
78,310 |
15.3% |
| OTHER UNDERGRADUATE | |||
| Total Students (end of period) |
25,043 |
24,209 |
3.4% |
| Average Total Students |
25,043 |
24,209 |
3.4% |
| Average Total Students (ex-Acquisitions)* |
21,882 |
24,209 |
-9.6% |
| Tuition Fees (Total – R$ ‘000) |
77,174 |
69,182 |
11.6% |
| Tuition Fees (ex- Acquisitions* – R$ ‘000) |
66,889 |
69,182 |
-3.3% |
| TOTAL TUITION FEES | |||
| Tuition Fees (Total – R$ ‘000) |
806,101 |
649,015 |
24.2% |
| Tuition Fees (ex- Acquisitions* – R$ ‘000) |
730,932 |
649,015 |
12.6% |
| *For the three months period ended March 31, 2023, “2023 Ex Acquisitions” excludes: Alem da Medicina (January & February 2023; Closing of Alem da Medicina was in March, 2022), Glic, Cardiopapers and UNIT Alagoas and FITS Jaboatão dos Guararapes (all from January to March, 2023). | |||
Key Revenue Drivers – Continuing Education and Digital Services
| Table 3: Key Revenue Drivers | Three months period ended March 31, | ||
|
2023 |
2022 |
% Chg |
|
| Continuing Education | |||
| Medical Specialization & Others | |||
| Total Students (end of period) |
4,774 |
3,479 |
37.2% |
| Average Total Students |
4,774 |
3,479 |
37.2% |
| Average Total Students (ex-Acquisitions) |
4,774 |
3,479 |
37.2% |
| Net Revenue from courses (Total – R$ ‘000) |
34,960 |
23,851 |
46.6% |
| Net Revenue from courses (ex- Acquisitions¹) |
34,960 |
23,851 |
46.6% |
| Digital Services | |||
| Content & Technology for Medical Education | |||
| Medcel Active Payers | |||
| Prep Courses & CME – B2P |
6,147 |
11,673 |
-47.3% |
| Prep Courses & CME – B2B |
5,988 |
4,574 |
30.9% |
| Além da Medicina Active Payers |
6,222 |
6,345 |
-1.9% |
| Cardiopapers Active Payers |
7,083 |
– |
– |
| Medical Harbour Active Payers |
21,686 |
– |
– |
| Clinical Decision Software | |||
| Whitebook Active Payers |
143,832 |
131,193 |
9.6% |
| Clinical Management Tools² | |||
| iClinic Active Payers |
23,740 |
19,622 |
21.0% |
| Shosp Active Payers |
2,881 |
2,278 |
26.5% |
| Digital Services Total Active Payers (end of period) |
217,579 |
175,685 |
23.8% |
| Net Revenue from Services (Total – R$ ‘000) |
56,792 |
47,477 |
19.6% |
| Net Revenue – B2P |
46,603 |
41,197 |
13.1% |
| Net Revenue – B2B |
10,187 |
6,280 |
62.2% |
| Net Revenue From Services (ex-Acquisitions¹) |
49,834 |
47,477 |
5.0% |
| *For the three months period ended March 31, 2023, “2023 Ex Acquisitions” excludes: Alem da Medicina (January & February 2023; Closing of Alem da Medicina was in March, 2022), Glic, Cardiopapers and UNIT Alagoas and FITS Jaboatão dos Guararapes (all from January to March, 2023). | |||
| (2) Clinical management tools includes Telemedicine and Digital Prescription features. | |||
Key Operational Drivers – Digital Services
Monthly Active Users (MaU) represents the number of unique individuals that consumed Digital Services content in each one of our products in the last 30 days of a specific period. Total monthly active users reached almost 295 thousand, 13.6% higher than the same period of last year.
Monthly Unique Active Users (MuaU) represents the number of unique individuals, without overlap of users among products, in the last 30 days of a specific period.
| Table 4: Key Operational Drivers for Digital Services – Monthly Active Users (MaU) | ||||
|
1Q23 |
1Q22 |
% Chg YoY |
4Q22 |
|
| Content & Technology for Medical Education |
31,549 |
21,464 |
47.0% |
16,539 |
| Clinical Decision Software |
237,003 |
218,313 |
8.6% |
221,762 |
| Clinical Management Tools¹ |
24,568 |
19,762 |
24.3% |
20,936 |
| Physician-Patiet Relationship |
1,773 |
– |
1,473 |
|
| Total Monthly Active Users (MaU) – Digital Services |
294,893 |
259,539 |
13.6% |
260,710 |
| 1) Clinical management tools includes Telemedicine and Digital Prescription features | ||||
| Includes Shosp, Medicinae and Além da Medicina starting in 1Q22 and Cardiopapers and Glic starting in 2Q22 | ||||
| Table 5: Key Operational Drivers for Digital Services – Monthly Unique Active Users (MuaU) | ||||
|
1Q23 |
1Q22 |
% Chg QoQ |
4Q22 |
|
| Total Monthly Unique Active Users (MuaU) – Digital Services |
262,137 |
242,374 |
8.2% |
241,949 |
| 1) Total Monthly Unique Active Users excludes non-integrated companies: Medical Harbour, Medicinae, Shosp, Além da Medicina, Cardiopapers and Glic | ||||
Seasonality
Undergrad’s tuition revenues are related to the intake process and monthly tuition fees charged to students over the period; thus does not have significant fluctuations during the semester. Continuing Education revenues are related to monthly intakes and tuition fees and do not have a considerable concentration in any period. Digital Services is comprised mainly of Medcel, Pebmed, and iClinic revenues. While Pebmed and iClinic do not have significant fluctuation regarding seasonality, Medcel’s revenue is concentrated in the first and last quarter of the year due to the enrollments of Medcel’s clients period. In addition, the majority of Medcel’s revenues are derived from printed books and e-books, which are recognized at the point in time when control is transferred to the customer. Consequently, the Digital Services segment generally has higher revenues and results of operations in the first and last quarters of the year than in the second and third quarters.
Revenue
Adjusted Net Revenue for the first quarter of 2023 was R$709.4 million, an increase of 25.0% over the same period of the prior year, mainly due to higher tickets in Medicine courses in 8.3%, maturation of medical seats, the beginning of 4 Mais Médicos campuses, consolidation of UNIT Alagoas and FITS Jaboatão dos Guararapes acquisition, the Continuing Education high performance and Digital Services execution.
The Digital Services segment increased 19.6% year over year, a combination of (a) B2B engagements, and (b) expansion of the active payers in the B2P, mainly in Whitebook, iClinic, and Shosp, partially offset by the lower performance of Medcel, due to a higher competition scenario in the Residency Preparatory market; and (c) consolidation of Alem da Medicina, Glic, and Cardiopapers.
| Table 6: Revenue & Revenue Mix | ||||||
| (in thousands of R$) | For the three months period ended March 31, | |||||
|
2023 |
2023 Ex Acquisitions* |
2022 |
% Chg |
% Chg Ex Acquisitions |
||
| Net Revenue Mix | ||||||
| Undergrad |
620,976 |
562,822 |
495,395 |
25.3% |
13.6% |
|
| Adjusted Undergrad¹ |
620,398 |
562,244 |
496,787 |
24.9% |
13.2% |
|
| Continuing Education |
34,960 |
34,960 |
23,851 |
46.6% |
46.6% |
|
| Digital Services |
56,792 |
49,834 |
47,477 |
19.6% |
5.0% |
|
| Inter-segment transactions |
– 2,767 |
– 2,767 |
– 399 |
n.a |
593.5% |
|
| Total Reported Net Revenue |
709,961 |
644,849 |
566,324 |
25.4% |
13.9% |
|
| Total Adjusted Net Revenue ¹ |
709,383 |
644,271 |
567,716 |
25.0% |
13.5% |
|
| *For the three months period ended March 31, 2023, “2023 Ex Acquisitions” excludes: Alem da Medicina (January & February 2023; Closing of Alem da Medicina was in March, 2022), Glic, Cardiopapers and UNIT Alagoas and FITS Jaboatão dos Guararapes (all from January to March, 2023). | ||||||
| (1) Includes mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction and excludes any recovery of these discounts that were invoiced based on the Supreme Court decision. | ||||||
| (2) See more information on “Non-GAAP Financial Measures” (Item 07). |
Adjusted EBITDA
Adjusted EBITDA for the three-month period ended March 31, 2023, increased 21.9% to R$330.2 million, up from R$270.8 million in the same period of the prior year, and the Adjusted EBITDA Margin decreased 120 basis points to 46.5%. The Adjusted EBITDA Margin reduction is mainly due to the following: (a) Digital segment, primarily due to Medcel’s performance; and (b) consolidation of 4 new Mais Médicos campuses (operation started on 3Q22) and UNIT Alagoas and FITS Jaboatão dos Guararapes which are performing better than expected but still present lower margins when compared to the integrated companies.
| Table 7: Adjusted EBITDA | |||||
| (in thousands of R$) | For the three months period ended March 31, | ||||
|
2023 |
2023 Ex Acquisitions* |
2022 |
% Chg |
% Chg Ex Acquisitions |
|
| Adjusted EBITDA |
330,211 |
304,231 |
270,801 |
21.9% |
12.3% |
| % Margin |
46.5% |
47.2% |
47.7% |
-120 bps | -50 bps |
| *For the three months period ended March 31, 2023, “2023 Ex Acquisitions” excludes: Alem da Medicina (January & February 2023; Closing of Alem da Medicina was in March, 2022), Glic, Cardiopapers and UNIT Alagoas and FITS Jaboatão dos Guararapes (all from January to March, 2023). | |||||
Adjusted Net Income
Net Income for the first quarter of 2023 was R$117.8 million, a decrease of 12.7% over the same period of the prior year. Adjusted Net Income for the first quarter of 2023 was R$166.4 million, in line with the same period from the previous year, mainly due to better operational performance, which was offset by higher financial expenses, mainly related to the increase in leverage due to UNIT Alagoas and FITS Jaboatao business combination and higher interest rates, when compared to the same period of the prior year.
| Table 8: Adjusted Net Income | |||
| (in thousands of R$) | For the three months period ended March 31, | ||
|
2023 |
2022 |
% Chg |
|
| Net income |
117,772 |
134,942 |
-12.7% |
| Amortization of customer relationships and trademark (1) |
24,203 |
18,283 |
32.4% |
| Share-based compensation |
6,495 |
2,929 |
121.7% |
| Non-recurring expenses: |
17,907 |
11,027 |
62.4% |
| – Integration of new companies (2) |
5,900 |
4,171 |
41.5% |
| – M&A advisory and due diligence (3) |
11,039 |
1,212 |
810.8% |
| – Expansion projects (4) |
151 |
602 |
-74.9% |
| – Restructuring expenses (5) |
1,395 |
3,650 |
-61.8% |
| – Mandatory Discounts in Tuition Fees (6) |
– 578 |
1,392 |
n.a. |
| Adjusted Net Income |
166,377 |
167,181 |
-0.5% |
| Basic earnings per share – in R$ (7) |
1.25 |
1.42 |
-12.0% |
| Adjusted earnings per share – in R$ (8) |
1.77 |
1.77 |
0.0% |
| (1) Consists of amortization of customer relationships and trademark recorded under business combinations. | |||||
| (2) Consists of expenses related to the integration of newly acquired companies. | |||||
| (3) Consists of expenses related to professional and consultant fees in connection with due diligence services for our M&A transactions. | |||||
| (4) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses. | |||||
| (5) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of our acquired companies. | |||||
| (6) Consists of mandatory discounts in tuition fees granted by state decrees, individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction and excludes any recovery of these discounts that were invoiced based on the Supreme Court decision. | |||||
| (7) Basic earnings per share: Net Income/Weighted average number of outstanding shares. | |||||
| (8) Adjusted earnings per share: Adjusted Net Income attributable to equity holders of the Parent/Weighted average number of outstanding shares. | |||||
Cash and Debt Position
On March 31, 2023, Cash and Cash Equivalents were R$722.7 million, a decrease of 33.9% over December 31, 2022, due to UNIT Alagoas and FITS Jaboatão dos Guararapes business combination.
For the three-month period ended March 31, 2023, Afya reported Adjusted Cash Flow from Operations of R$349.4 million, up from R$293.6 million in the same period of the previous year, an increase of 19.0% YoY, boosted by the solid operational results. Operating Cash Conversion Ratio was 111.9% for the three-month period that ended on March 31, 2023.
On March 31, 2023, Net Debt, excluding the effect of IFRS 16, totaled R$2,029 million. When compared to December 31, 2022 Net Debt added to R$825 million related to UNIT Alagoas and FITS Jaboatão dos Guararapes business combination closed on January 2, 2023, the Net Debt reduced R$ 177 million due to the strong cash flow generation in the quarter.
The following table shows more information regarding the cost of debt of 1Q23, considering loans and financing, capital market, and accounts payable to selling shareholders. Afya’s capital structure remains solid with a conservative leveraging position and a low cost of debt.
| Table 9: Operating Cash Conversion Ratio Reconciliation | For the three months period ended March 31, | ||
| (in thousands of R$) | Considering the adoption of IFRS 16 | ||
|
2023 |
2022 |
% Chg |
|
| (a) Cash flow from operations |
331,554 |
278,715 |
19.0% |
| (b) Income taxes paid |
17,819 |
14,850 |
20.0% |
| (c) = (a) + (b) Adjusted cash flow from operations |
349,373 |
293,565 |
19.0% |
| (d) Adjusted EBITDA |
330,211 |
270,801 |
21.9% |
| (e) Non-recurring expenses: |
17,907 |
11,027 |
62.4% |
| – Integration of new companies (1) |
5,900 |
4,171 |
41.5% |
| – M&A advisory and due diligence (2) |
11,039 |
1,212 |
810.8% |
| – Expansion projects (3) |
151 |
602 |
-74.9% |
| – Restructuring Expenses (4) |
1,395 |
3,650 |
-61.8% |
| – Mandatory Discounts in Tuition Fees (5) |
-578 |
1,392 |
n.a. |
| (f) = (d) – (e) Adjusted EBITDA ex- non-recurring expenses |
312,304 |
259,774 |
20.2% |
| (g) = (c) / (f) Operating cash conversion ratio |
111.9% |
113.0% |
-110 bps |
| (1) Consists of expenses related to the integration of newly acquired companies. | |||
| (2) Consists of expenses related to professional and consultant fees in connection with due diligence services for M&A transactions. | |||
| (3) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses. | |||
| (4) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of acquired companies. | |||
| (5) Consists of mandatory discounts in tuition fees granted by state decrees, individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction and excludes any recovery of these discounts that were invoiced based on the Supreme Court decision. | |||
| Table 10: Gross Debt and Average Cost of Debt | ||||
| (in millions of R$) | For the three months period ended March 31, | |||
| Cost of Debt | ||||
| Gross Debt | Duration (Years) | per year | %CDI* | |
| Loans and financing: Softbank |
825 |
3.1 |
6.5% |
48% |
| Capital Market |
519 |
4.4 |
15.7% |
114% |
| Loans and financing: Others |
580 |
1.9 |
15.7% |
114% |
| Accounts payable to selling shareholders |
828 |
1.2 |
13.3% |
97% |
| Average |
2,751 |
2.6 |
12.1% |
89% |
| **Based on the annualized Interbank Certificates of Deposit (“CDI”) rate for the period as a reference: 1Q23: ~13.65% p.y. |
||||
| Table 11: Cash and Debt Position | |||||
| (in thousands of R$) | |||||
|
1Q23 |
FY2022 |
% Chg |
1Q22 |
% Chg |
|
| (+) Cash and Cash Equivalents |
722,691 |
1,093,082 |
-33.9% |
789,435 |
-8.5% |
| Cash and Bank Deposits |
28,375 |
57,509 |
-50.7% |
42,648 |
-33.5% |
| Cash Equivalents |
694,316 |
1,035,573 |
-33.0% |
746,787 |
-7.0% |
| (-) Loans and Financing |
1,923,737 |
1,882,901 |
2.2% |
1,388,841 |
38.5% |
| Current |
193,214 |
145,202 |
33.1% |
142,654 |
35.4% |
| Non-Current |
1,730,523 |
1,737,699 |
-0.4% |
1,246,187 |
38.9% |
| (-) Accounts Payable to Selling Shareholders |
769,274 |
528,678 |
45.5% |
698,413 |
10.1% |
| Current |
417,398 |
261,711 |
59.5% |
264,520 |
57.8% |
| Non-Current |
351,876 |
266,967 |
31.8% |
433,893 |
-18.9% |
| (-) Other Short and Long Term Obligations |
58,702 |
62,176 |
-5.6% |
70,880 |
-17.2% |
| (=) Net Debt (Cash) excluding IFRS 16 |
2,029,022 |
1,380,673 |
47.0% |
1,368,699 |
48.2% |
| (-) Lease Liabilities |
864,983 |
769,525 |
12.4% |
733,420 |
17.9% |
| Current |
38,026 |
32,459 |
17.2% |
27,750 |
37.0% |
| Non-Current |
826,957 |
737,066 |
12.2% |
705,670 |
17.2% |
| Net Debt (Cash) with IFRS 16 |
2,894,005 |
2,150,198 |
34.6% |
2,102,119 |
37.7% |
Contacts
Investor Relations Contact:
Afya Limited
ir@afya.com.br
Media Contact:
Cíntia Moraes Marin
cintia.marin@afya.com.br
